Citigroup’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-3,400
Closed -$8.02K 5913
2024
Q4
$8.02K Sell
3,400
-49,400
-94% -$868K ﹤0.01% 5412
2024
Q3
$1.55M Buy
+52,800
New +$1.22M ﹤0.01% 2892
2024
Q1
Sell
-49,100
Closed -$1.11M 5828
2023
Q4
$1.11M Buy
+49,100
New +$1.04M ﹤0.01% 2743

Other funds holding FLNA

Citigroup's FLNA Position: Q1 2026 in Review

Citigroup reduced its Filana Therapeutics (FLNA) stake by 68% in Q1 2026, selling an estimated $86 and leaving 20 shares worth $34. The position accounts for ﹤0.01% of the portfolio, ranked #5672.

Citigroup first reported a position in FLNA in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.42M in Q3 2021. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • Citigroup held 20 shares of Filana Therapeutics worth $34 as of Q1 2026.
  • Citigroup sold 42 Filana Therapeutics shares in Q1 2026, an estimated $86.
  • Filana Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5672 holding.
  • Citigroup first reported a position in Filana Therapeutics in Q2 2013 and has held it in 38 quarters since.
  • Citigroup's Filana Therapeutics position peaked at $2.42M in Q3 2021.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.